Two of Europe's biotechnology companies are pooling their expertise to develop a new generation of eye and central nervous system (CNS) therapies, using encapsulated cell technology (ECT).
ECT is an implantable drug-delivery system, developed by the French company Neurotech, to allow the sustained, low-dose release of protein-based drugs to the eye and CNS. In the ECT system, living cells that produce therapeutic proteins are enclosed in an implantable, semi-permeable membrane. The membrane allows proteins to diffuse out of the capsule at a steady rate, but also allows nutrients to move in, feeding the cells and prolonging their therapeutic lifetime.
…
No comments:
Post a Comment